AU2022387106A1 - Protein tyrosine phosphatase inhibitors and methods of use thereof - Google Patents

Protein tyrosine phosphatase inhibitors and methods of use thereof Download PDF

Info

Publication number
AU2022387106A1
AU2022387106A1 AU2022387106A AU2022387106A AU2022387106A1 AU 2022387106 A1 AU2022387106 A1 AU 2022387106A1 AU 2022387106 A AU2022387106 A AU 2022387106A AU 2022387106 A AU2022387106 A AU 2022387106A AU 2022387106 A1 AU2022387106 A1 AU 2022387106A1
Authority
AU
Australia
Prior art keywords
methyl
fluoro
dihydro
amino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022387106A
Other languages
English (en)
Inventor
Naomi Anne BARTON
Andrew Bogdan
Claire Anne Marie CARIOU-MUMFORD
Elliot P. FARNEY
Jennifer M. Frost
Philip R. Kym
Christopher Patrick MCMAHON
Giuseppe Nano
Zhaoming Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Publication of AU2022387106A1 publication Critical patent/AU2022387106A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022387106A 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof Pending AU2022387106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278339P 2021-11-11 2021-11-11
US63/278,339 2021-11-11
PCT/US2022/049584 WO2023086498A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022387106A1 true AU2022387106A1 (en) 2024-05-23

Family

ID=84689141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022387106A Pending AU2022387106A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (1) US20250019374A1 (https=)
EP (1) EP4430038A1 (https=)
JP (1) JP2024543452A (https=)
CN (1) CN118525016A (https=)
AU (1) AU2022387106A1 (https=)
CA (1) CA3236854A1 (https=)
MX (1) MX2024005658A (https=)
WO (1) WO2023086498A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
WO2025026158A1 (zh) * 2023-07-28 2025-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
BR112020026086A2 (pt) * 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
WO2023086498A1 (en) 2023-05-19
CN118525016A (zh) 2024-08-20
EP4430038A1 (en) 2024-09-18
CA3236854A1 (en) 2023-05-19
US20250019374A1 (en) 2025-01-16
JP2024543452A (ja) 2024-11-21
MX2024005658A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
US12390437B2 (en) Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response
EP3455204B1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
AU2022387106A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
IL275058B2 (en) Sulfonylurea derivatives as modulators of the NLRP3 inflammasome
EP4200275A2 (en) Fumarate derivatives and their medical use
KR102444718B1 (ko) 아미노산 유도체의 전구약물
CN114685531B (zh) 四并环化合物及其药物组合物和应用
AU2020405536B2 (en) Benzimidazole derivatives
WO2021161105A1 (en) P2x3 modulators
RS63557B1 (sr) Derivati 2-okso-tiazola kao inhibitori a2a i jedinjenja za upotrebu u lečenju kancera
WO2022269251A1 (en) Acrylamide derivatives useful as anti-inflammatory agents
EP3707136B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
US20250320185A1 (en) Aminoheteroaryl kinase inhibitors
WO2021053158A1 (en) Novel histone methyltransferase inhibitors
US11718615B2 (en) Heterocyclic compounds and their application in medicine
US20230002366A1 (en) Indene derivatives useful in treating pain and inflammation
JP2024543451A (ja) プロテインチロシンホスファターゼ阻害剤及びその使用方法
EA046605B1 (ru) Агонисты gpr119